REACTIONS Sample Clauses

REACTIONS. All bearings 26-0-0. (lb) - Max Horz 2=-116(LC 15) Max Uplift All uplift 100 lb or less at joint(s) 34, 35, 36, 37, 38, 39, 40, 41, 32, 31, 30, 29, 28 except 2=-204(LC 18), 33=-103(LC 7), 42=-100(LC 10), 27=-448(LC 18), 26=-270(LC 7) Max Grav All reactions 250 lb or less at joint(s) 2, 34, 35, 36, 37, 38, 39, 40, 41, 31, 30, 29, 27 except 33=679(LC 1), 42=350(LC 1), 32=252(LC 18), 28=272(LC 18), 26=894(LC 18) FORCES. (lb) - Max. Comp./Max. Ten. - All forces 250 (lb) or less except when shown. TOP CHORD 2-3=-296/920, 3-4=-255/855, 4-5=-247/883, 5-6=-231/877, 6-7=-216/878, 7-8=-202/878, 8-9=-187/878, 9-10=-172/877, 10-11=-158/886, 11-12=-139/858, 12-13=-139/862, 13-14=-160/897, 14-15=-175/888, 15-16=-191/888, 16-17=-207/888, 17-18=-227/891, 18-19=-214/800, 19-20=-272/931, 20-21=-283/906, 21-22=-306/896 BOT CHORD 2-42=-792/323, 41-42=-792/323, 40-41=-792/323, 39-40=-792/323, 38-39=-792/323, 37-38=-792/323, 36-37=-792/323, 35-36=-792/323, 34-35=-792/323, 33-34=-792/323, 32-33=-792/323, 31-32=-792/323, 30-31=-792/323, 29-30=-792/323, 28-29=-792/323, 27-28=-792/323, 26-27=-792/323, 25-26=-792/323, 24-25=-792/323, 22-24=-792/323 WEBS 12-33=-660/114, 3-42=-276/122, 19-26=-442/146 NOTES- (13)
REACTIONS. All bearings 32-0-0. (lb) - Max Horz 2=-116(LC 11) Max Uplift All uplift 100 lb or less at joint(s) 2, 34, 35, 36, 37, 38, 39, 40, 41, 32, 31, 30, 29, 28, 27, 26, 25, 24, 22 except 42=-100(LC 10) Max Grav All reactions 250 lb or less at joint(s) 33, 34, 35, 36, 37, 38, 39, 40, 41, 32, 31, 30, 29, 28, 27, 26, 25 except 2=273(LC 17), 42=343(LC 1), 24=343(LC 1), 22=273(LC 18) FORCES. (lb) - Max. Comp./Max. Ten. - All forces 250 (lb) or less except when shown. WEBS 3-42=-270/122, 21-24=-270/122 NOTES- (13)
REACTIONS. All bearings 1-10-7. (lb) - Max Horz 1=-89(LC 6) Max Uplift All uplift 100 lb or less at joint(s) 6, 1, 4, 5 Max Grav All reactions 250 lb or less at joint(s) 6, 1, 4, 5 FORCES. (lb) - Max. Comp./Max. Ten. - All forces 250 (lb) or less except when shown. NOTES- (13)

Related to REACTIONS

  • Adverse Events Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange, the NASDAQ National Market or the NASDAQ Capital Market, (ii) a general moratorium on commercial banking activities in the People’s Republic of China or New York, (iii) the outbreak or escalation of hostilities involving the United States or the People’s Republic of China or the declaration by the United States or the People’s Republic of China of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States or the People’s Republic of China having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus.

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Product Complaints Subdistributor shall promptly notify Distributor of (but in no event later than 24 hours after receipt), and provide, upon Distributor’s request, reasonable assistance to address and investigate, any complaint or adverse claim about any Product or its use of which Subdistributor becomes aware;

  • Outcomes Provider’s services will result in the following:

  • Regulatory Actions The following provisions shall be applicable to the parties to the extent that they are required to be included in employment agreements between a savings bank and its employees pursuant to Section 563.39(b) of the Office of Thrift Supervision (“OTS”) Rules and Regulations, 12 C.F.R. §563.39(b), or any successor thereto, and shall be controlling in the event of a conflict with any other provision of this Agreement, including without limitation Section 5 hereof.

  • Adverse Event Reporting Company shall adhere, and shall require that its Affiliates, Sublicensees, co-marketers and distributors adhere, to all requirements of applicable law and regulations that relate to the reporting and investigation of any adverse event, including without limitation an unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease, whether or not considered Captisol or Licensed Product-related, which occurs or worsens following administration of Captisol or Licensed Product. Company shall provide CyDex with summaries of all reports of any such adverse event which is serious (any such adverse event involving Captisol **** that results in death, is life-threatening, requires or prolongs inpatient hospitalization, results in disability, congenital anomaly or is medically important (i.e., may require other medical or surgical intervention to prevent other serious criteria from occurring)) which Company has reason to believe are associated with Captisol within **** days following (i) Company’s submission of any such report to any regulatory agency, or (ii) receipt from Company’s Sublicensee, co-marketer or distributor of any such report to any regulatory agency. **** Reports from Company shall be delivered to the attention of Vice President, Chief Scientific Officer, CyDex, with a copy to Chief Executive Officer, CyDex, at the address set forth in Section 14.7. The parties shall mutually cooperate with regard to investigation of any such serious adverse event, whether experienced by Company, CyDex or any other Affiliate, Sublicensee, co-marketer or distributor of CyDex or Company.

  • Remedial Measures Upon becoming aware of an alleged security breach, Contractor’s Contract Manager must set up a conference call with the Department’s Contract Manager. The conference call invitation must contain a brief description of the nature of the event. When possible, a 30 minute notice will be given to allow Department personnel to be available for the call. If the designated time is not practical for the Department, an alternate time for the call will be scheduled. All available information must be shared on the call. The Contractor must answer all questions based on the information known at that time and answer additional questions as additional information becomes known. The Contractor must provide the Department with final documentation of the incident including all actions that took place. If the Contractor becomes aware of a security breach or security incident outside of normal business hours, the Contractor must notify the Department’s Contract Manager and in all events, within one business day.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Mold The OWNER/AGENT has inspected the unit prior to lease and knows of no damp or wet building materials and knows of no mold contamination. Resident agrees to accept full responsibility and maintain the premises in a manner that prevents the occurrence of an infestation of mold in the premises. Resident also agrees to immediately report to the OWNER/AGENT any evidence of water leaks, excessive moisture or lack of proper ventilation and evidence of mold that cannot be removed by cleaning.

  • No Adverse Events Between the date hereof and the Closing Date, neither the business, assets or condition, financial or otherwise, of the Company taken as a whole shall have been materially adversely affected in any manner.